BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|May 15, 2021
- Pharmaceutical Technology-05-15-2021
- Volume 2021 eBook
- Issue 2
Using ddPCR to Detect Mycoplasma Contamination
Author(s)Mark White
The sensitivity of droplet digital PCR helps manufacturers detect Mycoplasma contamination in AAV-based gene therapy products.
Advertisement
The accelerated pace of gene therapies is a sign of enhancements in our understanding of genetics and viral engineering as well as innovation in manufacturing processes. Despite this progress, gene therapy development is not a perfect science, and manufacturers must be careful to monitor the quality of their products before they reach patients. The sensitivity of droplet digital PCR (ddPCR) helps manufacturers detect Mycoplasma contamination in adeno-associated vector-based gene therapy products.
About the author
Mark White, PhD, is associate director, Biopharma Product Marketing, at Bio-Rad Laboratories.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing,May 2021
May 2021
Pages: 26–32
Citations
When referring to this article, please cite it as M. White, “Using ddPCR to Detect Mycoplasma Contamination," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).
Articles in this issue
over 5 years ago
Sterile Filtration: Reducing Risk, Ensuring Safetyover 5 years ago
Filling Small Batchesover 5 years ago
Breaking the Cold Chain for Vaccinesover 5 years ago
The Impact of COVID-19 on Biologics Regulationsover 5 years ago
Packaging Biologic Drugs for Clinical Trialsover 5 years ago
Tracking Technologies Guard Vaccine Cold Chainover 5 years ago
Eyeing Up Success in Fill/Finishover 5 years ago
Reducing Packaging Costs for Prefilled Syringesover 5 years ago
Biologics Facilities Expand and Establish New Locations in 2021Advertisement
Related to this article
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5